BostonGene
Founded Year
2015Stage
Series B | AliveTotal Raised
$200MValuation
$0000Last Raised
$150M | 2 yrs agoMosaic Score The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.
-61 points in the past 30 days
About BostonGene
BostonGene is a biomedical software company focused on advanced patient analysis and personalized therapy decision making in the fight against cancer. The company's main services include performing sophisticated analytics to aid clinicians in evaluating viable treatment options based on each patient's individual genetics, tumor and tumor microenvironment, clinical characteristics, and disease profile. BostonGene primarily sells to the healthcare industry, specifically in the field of oncology. It was founded in 2015 and is based in Waltham, Massachusetts.
Loading...
BostonGene's Product Videos
BostonGene's Products & Differentiators
Tumor Portrait™
BostonGene’s integrated genomic and transcriptomic solution provides a holistic 360° overview for each cancer patient. Our clinical pipeline distinguishes more than 62 cancer types and 129 subtypes, compressing all the information you need into one simple patient-specific report.
Loading...
Research containing BostonGene
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned BostonGene in 1 CB Insights research brief, most recently on Jul 7, 2022.
Expert Collections containing BostonGene
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
BostonGene is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.
Unicorns- Billion Dollar Startups
1,244 items
Digital Health
11,067 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Oncology Tech
457 items
This collection includes companies applying technology to cancer care, diagnosis, and treatment. Examples include vendors offering cancer detection and diagnosis, oncology clinical decision support, real-world data, and AI oncology drug discovery.
Digital Health 50
50 items
BostonGene Patents
BostonGene has filed 58 patents.
The 3 most popular patent topics include:
- molecular biology
- bioinformatics
- oncology
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
6/12/2018 | 5/14/2024 | Oncology, Cancer, Rare cancers, Molecular biology, Genomics | Grant |
Application Date | 6/12/2018 |
|---|---|
Grant Date | 5/14/2024 |
Title | |
Related Topics | Oncology, Cancer, Rare cancers, Molecular biology, Genomics |
Status | Grant |
Latest BostonGene News
Sep 17, 2024
WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leading provider of AI-based molecular and immune profiling solutions, and researchers from multiple cancer centers including, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Weill Cornell Medicine and Washington University School of Medicine in St. Louis and others, today announced the online publication of the manuscript “Deep Clinical Responses and Limited Inflammatory Toxicity in Patients with Relapsed/Refractory T-cell Ly
BostonGene Frequently Asked Questions (FAQ)
When was BostonGene founded?
BostonGene was founded in 2015.
Where is BostonGene's headquarters?
BostonGene's headquarters is located at University Office Park III, Waltham.
What is BostonGene's latest funding round?
BostonGene's latest funding round is Series B.
How much did BostonGene raise?
BostonGene raised a total of $200M.
Who are the investors of BostonGene?
Investors of BostonGene include NEC, Japan Industrial Partners and Impact Investment Capital.
Who are BostonGene's competitors?
Competitors of BostonGene include Tempus and 3 more.
What products does BostonGene offer?
BostonGene's products include Tumor Portrait™ and 3 more.
Who are BostonGene's customers?
Customers of BostonGene include Brigham & Women's, Dana Farber Cancer Institure, Johns Hopkins , Mass General and MD Anderson Cancer Center.
Loading...
Compare BostonGene to Competitors
Strata Oncology operates as a precision oncology company. The company offers services that integrate molecular profiling, decision support, and clinical trial participation into routine practice, providing care for cancer patients. Strata Oncology primarily serves healthcare providers, health systems, biopharma, and patients. It was founded in 2015 and is based in Ann Arbor, Michigan.
Pangea Biomed develops a multi-cancer and multi-therapy response predictor. It combines machine learning and deep ribonucleic acid (RNA) analysis to map tumor molecular signatures for personalized cancer care. The company aims to bring precision oncology to cancer patients through oncology drug development, and the empowerment of oncologists to treat patients. It was founded in 2018 and is based in Tel Aviv, Israel.
Perthera operates as a healthcare artificial intelligence company focusing on advancing precision medicine. The company offers an artificial intelligence (AI) enabled platform utilizing patient history and multi-omic testing results to match cancer patients with ranked therapy options, and accelerates clinical and therapeutic innovation. It was formerly known as Personalized Cancer Therapy. It primarily serves the healthcare industry in the oncology sector. It was founded in 2012 and is based in McLean, Virginia.
Syapse focuses on transforming real-world evidence into actionable insights within the healthcare sector. The company empowers healthcare organizations to collaborate and deliver patient insights to improve care, particularly for cancer patients. Syapse's services are primarily utilized by healthcare providers and organizations seeking to enhance patient outcomes through data-driven insights. Syapse was formerly known as BDLicense. It was founded in 2008 and is based in San Francisco, California.
MedySapiens specializes in digital healthcare through AI-driven genomics, focusing on accelerating precision medicine and diagnosis for rare diseases. The company offers solutions like NEOseq_ACTION®, which enables the examination of single nucleotide variants in genes related to actionable genetic rare diseases using Next Generation Sequencing from a small blood sample. It was founded in 2016 and is based in Seoul, South Korea.
Decode Health specializes in providing an AI platform as a service (PaaS) that focuses on precision medicine within the healthcare sector. The company offers solutions for pharmaceutical, diagnostic, and technology companies by leveraging multiomics, clinical data, social determinants of health, and other healthcare data sources to deliver actionable insights and accelerate research and development. Decode Health primarily serves the pharmaceutical industry, diagnostic research, and technology platforms seeking to enhance disease management and outcomes. It was founded in 2019 and is based in Nashville, Tennessee.
Loading...